Mylan CEO Heather Bresch is coming under new scrutiny for her company's decision to raise the price of lifesaving EpiPens more than fourfold over the past eight years.
For people who closely watch the pharmaceutical industry, Bresch is well-known. But among a broader audience, few people know who she is.
That is changing as Democratic presidential nominee Hillary Clinton, the American Medical Association and a number of U.S. senators are calling on Bresch to roll back the steep price hikes on EpiPens.
So, who is Bresch, and what is her backstory?
The CEO is the daughter of a U.S. senator. She reincorporated her U.S.-based drug company in the Netherlands, which cut its tax liability.
She also retroactively was awarded an MBA from West Virginia University while her dad was governor of that state despite not having enough academic credits. At the time, the university's president was both a former lobbyist for her drug company and a high school classmate of hers.
And Bresch has also overseen her company's increase in the price of EpiPens from $100 in 2008, to more than $600 for some customers today. During that time, her compensation has risen nearly 700 percent
When Bresch took over as CEO in 2012, Mylan's stock was trading at almost $22 per share. The shares are up 101 percent under her leadership. Revenue has risen 38.5 percent since she took over, to $9.47 billion at the end of 2015.
Bresch, 47, has been thrust in the spotlight in recent days after colleagues of her father Sen. Joe Manchin, D.-W.Va., in the Senate have expressed outrage about the stunning price hikes for EpiPen, a device that contains just a dollar or so's worth of the drug epinephrine.
EpiPens are used by people having an allergic reaction known as anaphylaxis, which can be fatal. People with allergies — or parents of children with allergies — are encouraged to have multiple sets of EpiPens for home, school and elsewhere. While insurance often covers some of the cost, many people have to pay out of pocket for the devices, sometimes up to the full price.
Clinton, a former senator from New York, on Wednesday called Mylan's price increases "outrageous," and "just the latest troubling example of a company taking advantage of its consumers."
"Since there is no apparent justification in this case" for the EpiPen price hikes "I am calling on Mylan to immediately reduce the price of EpiPens," Clinton said in a statement.
The AMA, the nation's largest doctors' group, earlier Wednesday said that "with lives on the line, we urge the manufacturer to do all it can to rein in these exorbitant costs."
Bresch, who has been CEO since 2012, did not return a request for comment from CNBC on Wednesday.
Neither did Mylan nor Bresch's father, Manchin, whose Senate colleagues are calling for hearings on the price of EpiPens, and one of whom, Sen. Amy Klobuchar, D-Minn., has asked for the Federal Trade Commission to investigate.